公开(公告)号：US20160228440A1

公开(公告)日：2016-08-11

申请号：US15017315

申请日：2016-02-05

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Michelle Nannini ,  Elizabeth Punnoose ,  Deepak Sampath ,  Jeffrey Wallin ,  Premal Patel

IPC: A61K31/517 ,  A61K31/4166

CPC classification number: A61K31/517 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4166 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/58 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07D239/70 ,  C07D403/12 ,  C07K16/40 ,  A61K2300/00

Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Abstract translation: 本发明提供组合，其包含a）式I化合物或其药学上可接受的盐，其中R 1，R 2，R 5，R 10和A具有说明书中定义的任何值; 和b）选自5-FU，铂药剂，甲酰四氢叶酸，伊立替康，多西他赛，多柔比星，吉西他滨，SN-38，卡培他滨，替莫唑胺，紫杉醇，贝伐珠单抗，依托单抗，他莫昔芬，雷帕霉素和拉帕替尼的一种或多种药剂。 这些组合对于治疗过度增殖性疾病如癌症特别有用。

公开(公告)号：US20250121058A1

公开(公告)日：2025-04-17

申请号：US18984106

申请日：2024-12-17

Applicant: GENENTECH, INC.

Inventor： Gail Lewis Phillips ,  Deepak Sampath ,  Ingrid Wertz

IPC: A61K39/395 ,  A61K31/496 ,  A61K31/635 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32 ,  G01N33/574

Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

公开(公告)号：US20240108616A1

公开(公告)日：2024-04-04

申请号：US18506606

申请日：2023-11-10

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395

CPC classification number: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/39558 ,  A61K2039/545

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20230226045A1

公开(公告)日：2023-07-20

申请号：US18157680

申请日：2023-01-20

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395

CPC classification number: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/39558 ,  A61K2039/545

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US10993942B2

公开(公告)日：2021-05-04

申请号：US16827650

申请日：2020-03-23

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61P35/02 ,  A61P35/00

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20200253963A1

公开(公告)日：2020-08-13

申请号：US16827650

申请日：2020-03-23

Applicant: GENENTECH, INC. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother

IPC: A61K31/496

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US09539251B2

公开(公告)日：2017-01-10

申请号：US14020761

申请日：2013-09-06

Applicant: Genentech, Inc. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother

IPC: A61K39/395 ,  A61K31/496

CPC classification number: A61K31/496 ,  A61K2300/00

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract translation: 本发明涉及涉及用于治疗患有癌症的患者，特别是表达CD20的癌症的II型抗CD20抗体和选择性Bcl-2抑制剂的组合疗法。

公开(公告)号：US20160158360A1

公开(公告)日：2016-06-09

申请号：US14959221

申请日：2015-12-04

Applicant: Genentech, Inc.

Inventor： Sairy Hernandez ,  Ira Mellman ,  Jing Qing ,  Deepak Sampath

IPC: A61K39/395 ,  A61K45/06

CPC classification number: A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/76

Abstract: Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.

Abstract translation: 提供了增强免疫应答和治疗癌症的组合物和方法。 组合物包含PD-1轴拮抗剂和HPK1拮抗剂。 PD-1拮抗剂包括PD-1拮抗剂，PD-L1拮抗剂和PD-L2拮抗剂。 PD-1轴拮抗剂可以抑制PD-L1和/或PD-L2与PD-1的结合。 HPK1拮抗剂包括抑制HPK1的丝氨酸/苏氨酸激酶活性的化合物。 增强免疫应答或治疗癌症的方法包括将PD-1轴拮抗剂和HPK1拮抗剂依次或同时施用于有需要的受试者。

公开(公告)号：US20140248262A1

公开(公告)日：2014-09-04

申请号：US14020761

申请日：2013-09-06

Applicant: F. Hoffmann-La Roche AG ,  Genentech, Inc.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother

IPC: A61K39/395 ,  A61K31/496

CPC classification number: A61K31/496 ,  A61K2300/00

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract translation: 本发明涉及涉及用于治疗患有癌症的患者，特别是表达CD20的癌症的II型抗CD20抗体和选择性Bcl-2抑制剂的组合疗法。

公开(公告)号：US20250152582A1

公开(公告)日：2025-05-15

申请号：US19030370

申请日：2025-01-17

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/00 ,  A61K39/395

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.